What's in Shanghai Hengrui Pharmaceutical Co., Ltd.'s pipeline?

Shanghai Hengrui Pharmaceutical Co., Ltd. has 38 drugs in our index: 1 marketed, 0 filed, 8 in Phase 3, 9 in Phase 2, 20 in Phase 1.

Which companies overlap with Shanghai Hengrui Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Jiangsu HengRui Medicine Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Pfizer, Ahn-Gook Pharmaceuticals Co.,Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-hengrui-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Shanghai Hengrui Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shanghai Hengrui Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 8 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 8 Phase 3 9 Phase 2 20 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Dexmedetomidine Hydrochloride Nasal Spray	Dexmedetomidine Hydrochloride Nasal Spray	marketed
SHR-A2102 for Injection	SHR-A2102 for Injection	phase 3	PD-1 inhibitor	PD-1	Oncology
Paclitaxel, Docetaxel, Irinotecan	Paclitaxel, Docetaxel, Irinotecan	phase 3	Microtubule inhibitor	Microtubules	Oncology
SHR-A1912	SHR-A1912	phase 3	PD-1 inhibitor	PD-1	Oncology
SHR-8068 injection	SHR-8068 injection	phase 3	PD-L1 inhibitor	PD-L1	Oncology
SHR-A1904	SHR-A1904	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β	Oncology
Sodium Chloride Physiological Solution	Sodium Chloride Physiological Solution	phase 3	Electrolyte replacement solution		Supportive Care / Fluid and Electrolyte Management
SHR6508 plus oral placebo tablets	SHR6508 plus oral placebo tablets	phase 3	small molecule	unknown	unknown
Adebrelimab injection	Adebrelimab injection	phase 3	PD-L1 inhibitor	PD-L1	Oncology

Therapeutic area mix

Oncology · 7
Supportive Care / Fluid and Electrolyte Management · 1
unknown · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Jiangsu HengRui Medicine Co., Ltd. · 4 shared drug classes
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 3 shared drug classes
Innovent Biologics (Suzhou) Co. Ltd. · 3 shared drug classes
Pfizer · 3 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 2 shared drug classes
Bio-Thera Solutions · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Hengrui Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai Hengrui Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-hengrui-pharmaceutical-co-ltd. Accessed 2026-05-18.